[go: up one dir, main page]

FR2903999B1 - Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee - Google Patents

Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee

Info

Publication number
FR2903999B1
FR2903999B1 FR0653028A FR0653028A FR2903999B1 FR 2903999 B1 FR2903999 B1 FR 2903999B1 FR 0653028 A FR0653028 A FR 0653028A FR 0653028 A FR0653028 A FR 0653028A FR 2903999 B1 FR2903999 B1 FR 2903999B1
Authority
FR
France
Prior art keywords
sc4mol
hyperseborrhea
acne
modulators
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0653028A
Other languages
English (en)
Other versions
FR2903999A1 (fr
Inventor
Fernand Labrie
Alfy Mohamed El
The Van Luu
Ezequiel L Calvo
Jerome Aubert
Isabelle Carlavan
Sophie Deret
Johannes Voegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0653028A priority Critical patent/FR2903999B1/fr
Priority to CA002656839A priority patent/CA2656839A1/fr
Priority to EP07823601A priority patent/EP2046974A2/fr
Priority to PCT/FR2007/051682 priority patent/WO2008009855A2/fr
Publication of FR2903999A1 publication Critical patent/FR2903999A1/fr
Application granted granted Critical
Publication of FR2903999B1 publication Critical patent/FR2903999B1/fr
Priority to US12/320,170 priority patent/US20100021892A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR0653028A 2006-07-19 2006-07-19 Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee Expired - Fee Related FR2903999B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0653028A FR2903999B1 (fr) 2006-07-19 2006-07-19 Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
CA002656839A CA2656839A1 (fr) 2006-07-19 2007-07-18 Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
EP07823601A EP2046974A2 (fr) 2006-07-19 2007-07-18 Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
PCT/FR2007/051682 WO2008009855A2 (fr) 2006-07-19 2007-07-18 Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
US12/320,170 US20100021892A1 (en) 2006-07-19 2009-01-21 Modulators of SC4MOL for treating acne or hyperseborrhea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0653028A FR2903999B1 (fr) 2006-07-19 2006-07-19 Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee

Publications (2)

Publication Number Publication Date
FR2903999A1 FR2903999A1 (fr) 2008-01-25
FR2903999B1 true FR2903999B1 (fr) 2008-09-05

Family

ID=37698074

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0653028A Expired - Fee Related FR2903999B1 (fr) 2006-07-19 2006-07-19 Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee

Country Status (5)

Country Link
US (1) US20100021892A1 (fr)
EP (1) EP2046974A2 (fr)
CA (1) CA2656839A1 (fr)
FR (1) FR2903999B1 (fr)
WO (1) WO2008009855A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938333A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de cidea dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938338B1 (fr) * 2008-11-13 2012-10-05 Galderma Res & Dev Modulateurs de l'acetyl-coenzyme a acyltransferase 1 ou 2 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938342A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Ciblage de modulateurs de ces1 et/ou ces3 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938341A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
JP5990888B2 (ja) * 2011-09-29 2016-09-14 公立大学法人 富山県立大学 ヒト由来メチルステロール酸化酵素を生産する組換体及びその利用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3294844B2 (ja) * 1990-04-30 2002-06-24 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ステロイド５α―リダクターゼ
US6278038B1 (en) * 1992-04-10 2001-08-21 Oregon Health And Science University Mammalian melanocortin receptors and uses
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6479733B1 (en) * 1998-11-13 2002-11-12 E. I. Du Pont De Nemours And Company Sterol metabolism enzymes
MXPA02007309A (es) * 2000-02-02 2002-11-29 Warner Lambert Co Inhibidores duales de la sintesis de los esteres de la cera y los esteres del colesterol para las enfermedades de las glandulas sebaceas.
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
BR0209510A (pt) * 2001-05-09 2006-02-07 Univ Cleveland Hospitals Conjunto de genes marcadores, método para avaliar os efeitos protetores reparadores e/ou terapêuticos à radiação ultravioleta de um composto ou material, composto ou material tendo efeitos protetores, reparadores ou terapêuticos da radiação ultravioleta, métodos para melhorar e/ou tratar, para reverter e/ou reparar pele fotoavariada ou fotoenvelhecida, e para avaliar se uma substância pode reparar ou reverter os efeitos de fotoavaria ou fotoenvelhecimento relacionados com à exposição à radiação uv, substância ou material tendo efeitos reparadores ou de reversão da fotoavaria ou fotoenvelhecimento, composição ou formulação, formulação anti-fotoavaria ou anti-fotoenvelhecimento fotoprotetora ou terapêutica, métodos para avaliar a avaria na pele ou um substituto de pele induzida por radiação ultravioleta, em seguida à exposição à radiação uv, para prevenir pele fotoenvelhecida ou fotoavariada, para identificar ou selecionar indivìduos que são susceptìveis ou altamente sensìveis à fotoavaria ou fotoenvelhecimento da pele, em seguida à exposição à radiação uv, e, kit para avaliar as propiedades de fotoavaria ou fotoenvelhecimento de uma substância
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters

Also Published As

Publication number Publication date
WO2008009855A3 (fr) 2008-04-10
EP2046974A2 (fr) 2009-04-15
FR2903999A1 (fr) 2008-01-25
WO2008009855A2 (fr) 2008-01-24
CA2656839A1 (fr) 2008-01-24
US20100021892A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
FR20C1066I2 (fr) Pièges à gdf pour l'utilisation dans le traitment de l'anémie
EP1986652A4 (fr) Aminotétrahydropyrannes en tant qu'inhibiteurs de dipeptidylpeptidase-iv dans le traitement prophylactique ou thérapeutique du diabète
EP1994181A4 (fr) Identification et utilisation de novopeptides pour le traitement du cancer
EP2217697A4 (fr) Utilisation des antagonistes de lingo-4 dans le traitement d'états mettant en jeu une démyélination
FR2889057B1 (fr) Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
EP2185202A4 (fr) Utilisation de l'interleukine-22 dans le traitement de la stéatose hépatique
BRPI0819582A2 (pt) "sistema de tratamento de líquido"
EP2139475A4 (fr) Utilisation d'inhibiteurs pde7 dans le traitement des troubles du
BRPI0916125A2 (pt) "dispositivo de tratamento"
BRPI0809272A2 (pt) Compostos de biaril e biheteroaril no tratamento de distúrbios do ferro
EP2020970A4 (fr) Traitement de l'oeil
EP1845773A4 (fr) Solution de perfusion et/ou de conservation pour organes
EP2318422A4 (fr) Aminoglycosides améliorés au plan de l'hydrophobicité
EP2171096A4 (fr) Polymorphismes de carboxylestérase-1 etleurs méthodes d'utilisation
EP2211861A4 (fr) Clioquinol dans le traitement de malignités hématologiques
EP2400980A4 (fr) Agents thérapeutiques de visfatine pour traiter l'acné et d'autres conditions
FR2887450B1 (fr) Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
FR2902324B1 (fr) Utilisation d'acide ellagique pour le traitement de la canitie
EP1865972A4 (fr) Traitement ou prevention du cancer et de troubles precancereux
FR2926020B1 (fr) Composition cosmetique et/ou dermatologique
FI20095661L (fi) Toimijan henkilöllisyyden varmennus
EP2484670A4 (fr) Substitués 1,2,4-tiadiazoles-5-imino utiles dans le traitement de maladies neurodégénératives
FR2899476B1 (fr) Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130329